Tetra-arsenic tetra-sulfide enhances NK-92MI mediated cellular immunotherapy in all-trans retinoic acid-resistant acute promyelocytic leukemia
In conclusion, our findings confirmed the potential of As4S4 as an adjuvant for NK-92MI in the treatment of ATRA-resistant APL. (Source: Investigational New Drugs)
Source: Investigational New Drugs - October 26, 2022 Category: Drugs & Pharmacology Source Type: research
Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer
AbstractCompared to chemotherapy alone, monoclonal antibodies like ipilimumab and nivolumab, with or without chemotherapy, improve the prognosis of patients with non-small cell lung cancer (NSCLC), albeit with a higher incidence of immune-related adverse events (irAEs) than those with immune checkpoint inhibitor (ICI) monotherapy. Therefore, we aimed to investigate if baseline overall tumor burden was associated with the development of Grade ≥ 3 irAEs (severe irAEs) when treated with first-line ipilimumab plus nivolumab with or without chemotherapy.We retrospectively examined consecutive patients with advanced NSCLC...
Source: Investigational New Drugs - October 21, 2022 Category: Drugs & Pharmacology Source Type: research
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161
This study activated on February 1, 2017, the required pre-determined number of patients (n = 13) had entered by November 5, 2018 for the first stage response evaluation. The accrual of this trial was formally terminated on December 27, 2019 as no response had been observed after the first stage accrual. Treatment-related grade 3 adverse events were reported in eight (61%) patients with hyperglycemia being the most fr equent, in three patients (23%). Other toxicities noted in the trial included fatigue, rash diarrhea, nausea, and vomiting. The median PFS was 5.19 months (95% CI [3.84, 9.30]) and the median OS was 20.4...
Source: Investigational New Drugs - October 20, 2022 Category: Drugs & Pharmacology Source Type: research
Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer
SummaryPembrolizumab treatment is associated with a favorable prognosis in patients with non-small-cell lung cancer (NSCLC). Here, we investigated the associations among pre-treatment clinical factors, baseline overall tumor burden, and development of severe immune-related adverse events (irAEs; grade ≥ 3) after pembrolizumab treatment with or without chemotherapy. We retrospectively examined consecutive patients with advanced NSCLC who received pembrolizumab with or without chemotherapy at Hakodate Goryoukaku Hospital from March 2017 to February 2021. The baseline overall tumor burden was measured as the sum of the...
Source: Investigational New Drugs - October 13, 2022 Category: Drugs & Pharmacology Source Type: research
Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating Neuropathies
Adv Ther (Weinh). 2022 Jun;5(6):2200030. doi: 10.1002/adtp.202200030. Epub 2022 Apr 5.ABSTRACTChronic autoimmune demyelinating neuropathies are a group of rare neuromuscular disorders with complex, poorly characterized etiology. Here we describe a phenotypic, human-on-a-chip (HoaC) electrical conduction model of two rare autoimmune demyelinating neuropathies, chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), and explore the efficacy of TNT005, a monoclonal antibody inhibitor of the classical complement pathway. Patient sera was shown to contain anti-GM1 IgM and IgG antibodies c...
Source: Adv Data - October 10, 2022 Category: Epidemiology Authors: John W Rumsey Case Lorance Max Jackson Trevor Sasserath Christopher W McAleer Christopher J Long Arindom Goswami Melissa A Russo Shruti M Raja Karissa L Gable Doug Emmett Lisa D Hobson-Webb Manisha Chopra James F Howard Jeffrey T Guptill Michael J Storek Source Type: research
Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating Neuropathies
Adv Ther (Weinh). 2022 Jun;5(6):2200030. doi: 10.1002/adtp.202200030. Epub 2022 Apr 5.ABSTRACTChronic autoimmune demyelinating neuropathies are a group of rare neuromuscular disorders with complex, poorly characterized etiology. Here we describe a phenotypic, human-on-a-chip (HoaC) electrical conduction model of two rare autoimmune demyelinating neuropathies, chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), and explore the efficacy of TNT005, a monoclonal antibody inhibitor of the classical complement pathway. Patient sera was shown to contain anti-GM1 IgM and IgG antibodies c...
Source: Adv Data - October 10, 2022 Category: Epidemiology Authors: John W Rumsey Case Lorance Max Jackson Trevor Sasserath Christopher W McAleer Christopher J Long Arindom Goswami Melissa A Russo Shruti M Raja Karissa L Gable Doug Emmett Lisa D Hobson-Webb Manisha Chopra James F Howard Jeffrey T Guptill Michael J Storek Source Type: research
Distinct mechanism of cervical cancer cell death caused by the investigational new drug SHetA2
Drug-targetable vulnerabilities of cancer cells include their dependence on heat shock proteins (HSPs) to support elevated mitochondrial metabolism and counteract cell death factors. The investigational new drug SHetA2 targets these vulnerabilities in ovarian and endometrial cancer cells by disrupting complexes of the mortalin HSP with its client proteins (mitochondrial support proteins, metabolic enzymes, p53) leading to mitochondrial leakage of cytochrome c and apoptosis-inducing factor (AIF), and caspase-dependent apoptosis. Our objective was to evaluate the roles of mitochondrial damage and another SHetA2-target HSP pr...
Source: Frontiers in Oncology - September 20, 2022 Category: Cancer & Oncology Source Type: research
Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022
MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1190-1195. doi: 10.15585/mmwr.mm7137e1.ABSTRACTCurrently, no Food and Drug Administration (FDA)-approved treatments for human monkeypox are available. Tecovirimat (Tpoxx), however, is an antiviral drug that has demonstrated efficacy in animal studies and is FDA-approved for treating smallpox. Use of tecovirimat for treatment of monkeypox in the United States is permitted only through an FDA-regulated Expanded Access Investigational New Drug (EA-IND) mechanism. CDC holds a nonresearch EA-IND protocol that facilitates access to and use of tecovirimat for treatment of monkeypox.§...
Source: MMWR Morb Mortal Wkl... - September 15, 2022 Category: Epidemiology Authors: Kevin O'Laughlin Farrell A Tobolowsky Riad Elmor Rahsaan Overton Siobh án M O'Connor Inger K Damon Brett W Petersen Agam K Rao Kevin Chatham-Stephens Patricia Yu Yon Yu CDC Monkeypox Tecovirimat Data Abstraction Team Source Type: research
Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022
MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1190-1195. doi: 10.15585/mmwr.mm7137e1.ABSTRACTCurrently, no Food and Drug Administration (FDA)-approved treatments for human monkeypox are available. Tecovirimat (Tpoxx), however, is an antiviral drug that has demonstrated efficacy in animal studies and is FDA-approved for treating smallpox. Use of tecovirimat for treatment of monkeypox in the United States is permitted only through an FDA-regulated Expanded Access Investigational New Drug (EA-IND) mechanism. CDC holds a nonresearch EA-IND protocol that facilitates access to and use of tecovirimat for treatment of monkeypox.§...
Source: MMWR Morb Mortal Wkl... - September 15, 2022 Category: Epidemiology Authors: Kevin O'Laughlin Farrell A Tobolowsky Riad Elmor Rahsaan Overton Siobh án M O'Connor Inger K Damon Brett W Petersen Agam K Rao Kevin Chatham-Stephens Patricia Yu Yon Yu CDC Monkeypox Tecovirimat Data Abstraction Team Source Type: research
Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022
MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1190-1195. doi: 10.15585/mmwr.mm7137e1.ABSTRACTCurrently, no Food and Drug Administration (FDA)-approved treatments for human monkeypox are available. Tecovirimat (Tpoxx), however, is an antiviral drug that has demonstrated efficacy in animal studies and is FDA-approved for treating smallpox. Use of tecovirimat for treatment of monkeypox in the United States is permitted only through an FDA-regulated Expanded Access Investigational New Drug (EA-IND) mechanism. CDC holds a nonresearch EA-IND protocol that facilitates access to and use of tecovirimat for treatment of monkeypox.§...
Source: MMWR Morb Mortal Wkl... - September 15, 2022 Category: Epidemiology Authors: Kevin O'Laughlin Farrell A Tobolowsky Riad Elmor Rahsaan Overton Siobh án M O'Connor Inger K Damon Brett W Petersen Agam K Rao Kevin Chatham-Stephens Patricia Yu Yon Yu CDC Monkeypox Tecovirimat Data Abstraction Team Source Type: research
Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022
MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1190-1195. doi: 10.15585/mmwr.mm7137e1.ABSTRACTCurrently, no Food and Drug Administration (FDA)-approved treatments for human monkeypox are available. Tecovirimat (Tpoxx), however, is an antiviral drug that has demonstrated efficacy in animal studies and is FDA-approved for treating smallpox. Use of tecovirimat for treatment of monkeypox in the United States is permitted only through an FDA-regulated Expanded Access Investigational New Drug (EA-IND) mechanism. CDC holds a nonresearch EA-IND protocol that facilitates access to and use of tecovirimat for treatment of monkeypox.§...
Source: MMWR Morb Mortal Wkl... - September 15, 2022 Category: Epidemiology Authors: Kevin O'Laughlin Farrell A Tobolowsky Riad Elmor Rahsaan Overton Siobh án M O'Connor Inger K Damon Brett W Petersen Agam K Rao Kevin Chatham-Stephens Patricia Yu Yon Yu CDC Monkeypox Tecovirimat Data Abstraction Team Source Type: research
Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022
MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1190-1195. doi: 10.15585/mmwr.mm7137e1.ABSTRACTCurrently, no Food and Drug Administration (FDA)-approved treatments for human monkeypox are available. Tecovirimat (Tpoxx), however, is an antiviral drug that has demonstrated efficacy in animal studies and is FDA-approved for treating smallpox. Use of tecovirimat for treatment of monkeypox in the United States is permitted only through an FDA-regulated Expanded Access Investigational New Drug (EA-IND) mechanism. CDC holds a nonresearch EA-IND protocol that facilitates access to and use of tecovirimat for treatment of monkeypox.§...
Source: MMWR Morb Mortal Wkl... - September 15, 2022 Category: Epidemiology Authors: Kevin O'Laughlin Farrell A Tobolowsky Riad Elmor Rahsaan Overton Siobh án M O'Connor Inger K Damon Brett W Petersen Agam K Rao Kevin Chatham-Stephens Patricia Yu Yon Yu CDC Monkeypox Tecovirimat Data Abstraction Team Source Type: research
Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022
MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1190-1195. doi: 10.15585/mmwr.mm7137e1.ABSTRACTCurrently, no Food and Drug Administration (FDA)-approved treatments for human monkeypox are available. Tecovirimat (Tpoxx), however, is an antiviral drug that has demonstrated efficacy in animal studies and is FDA-approved for treating smallpox. Use of tecovirimat for treatment of monkeypox in the United States is permitted only through an FDA-regulated Expanded Access Investigational New Drug (EA-IND) mechanism. CDC holds a nonresearch EA-IND protocol that facilitates access to and use of tecovirimat for treatment of monkeypox.§...
Source: MMWR Morb Mortal Wkl... - September 15, 2022 Category: Epidemiology Authors: Kevin O'Laughlin Farrell A Tobolowsky Riad Elmor Rahsaan Overton Siobh án M O'Connor Inger K Damon Brett W Petersen Agam K Rao Kevin Chatham-Stephens Patricia Yu Yon Yu CDC Monkeypox Tecovirimat Data Abstraction Team Source Type: research
Cardiovascular waveforms - can we extract more from routine signals?
JRSM Cardiovasc Dis. 2022 Sep 7;11:20480040221121438. doi: 10.1177/20480040221121438. eCollection 2022 Jan-Dec.ABSTRACTCardiovascular waveforms such as blood pressure, ECG and photoplethysmography (PPG), are routinely acquired by specialised monitoring devices. Such devices include bedside monitors, wearables and radiotelemetry which sample at very high fidelity, yet most of this numerical data is disregarded and focus tends to reside on single point averages such as the maxima, minima, amplitude, rate and intervals. Whilst, these measures are undoubtedly of value, we may be missing important information by simplifying the...
Source: Atherosclerosis - September 12, 2022 Category: Cardiology Authors: Manasi Nandi Mary Anton Jane V Lyle Source Type: research
Malaria Surveillance - United States, 2018
This report summarizes confirmed malaria cases in persons with onset of illness in 2018 and trends in previous years.DESCRIPTION OF SYSTEM: Malaria cases diagnosed by blood smear microscopy, polymerase chain reaction, or rapid diagnostic tests are reported to local and state health departments through electronic laboratory reports or by health care providers or laboratory staff members directly reporting to CDC or health departments. Case investigations are conducted by local and state health departments, and reports are transmitted to CDC through the National Malaria Surveillance System (NMSS), the National Notifiable Dis...
Source: MMWR Surveill Summ - September 1, 2022 Category: Epidemiology Authors: Kimberly E Mace Naomi W Lucchi Kathrine R Tan Source Type: research
